Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.04)
# 2,913
Out of 4,877 analysts
172
Total ratings
37.13%
Success rate
-7.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $48.72 | +76.52% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $1.97 | +205.34% | 3 | Jun 25, 2025 | |
| EXEL Exelixis | Maintains: Market Outperform | $47 → $50 | $44.11 | +13.35% | 22 | Jun 23, 2025 | |
| ELEV Elevation Oncology | Reiterates: Market Perform | n/a | $0.37 | - | 8 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $4.91 | +205.50% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.33 | +158.06% | 13 | May 29, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $2.56 | +134.38% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $11.78 | +69.78% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $4.70 | +91.49% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $1.54 | +289.61% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.64 | +394.51% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $3.82 | +424.25% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.20 | +1,322.59% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $0.32 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $70 | $5.61 | +1,147.77% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.64 | +527.45% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.41 | +515.84% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.22 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.49 | +304.04% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $313.03 | -10.55% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.73 | +67.83% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.44 | - | 10 | Jan 19, 2023 |
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $48.72
Upside: +76.52%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.97
Upside: +205.34%
Exelixis
Jun 23, 2025
Maintains: Market Outperform
Price Target: $47 → $50
Current: $44.11
Upside: +13.35%
Elevation Oncology
Jun 10, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.37
Upside: -
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.91
Upside: +205.50%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.33
Upside: +158.06%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $2.56
Upside: +134.38%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $11.78
Upside: +69.78%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.70
Upside: +91.49%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $1.54
Upside: +289.61%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.64
Upside: +394.51%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $3.82
Upside: +424.25%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.20
Upside: +1,322.59%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.32
Upside: -
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $5.61
Upside: +1,147.77%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.64
Upside: +527.45%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.41
Upside: +515.84%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.22
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.49
Upside: +304.04%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $313.03
Upside: -10.55%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.73
Upside: +67.83%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.44
Upside: -